Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Jan 1.

Published in final edited form as: J Cardiovasc Pharmacol Ther. 2013 Nov 28;19(1):121–132. doi: 10.1177/1074248413508003

Anatomic no-reflow in hearts given 0.05 mg/kg/hr Bendavia beginning 10 minutes after the onset of reperfusion. (A). No-reflow, expressed as either a percentage of the risk zone, or a percentage of the necrotic zone, was no different between control and Bendavia-treated rabbits (P>0.05 for both comparisons). (B). Relationship between no-reflow zone and the ischemic risk zone. There was no significant group effect when Bendavia administration began 10 minutes after the onset of reperfusion (P > 0.05, ANCOVA).

Anatomic no-reflow in hearts given 0.05 mg/kg/hr Bendavia beginning 10 minutes after the onset of reperfusion. (A). No-reflow, expressed as either a percentage of the risk zone, or a percentage of the necrotic zone, was no different between control and Bendavia-treated rabbits (P>0.05 for both comparisons). (B). Relationship between no-reflow zone and the ischemic risk zone. There was no significant group effect when Bendavia administration began 10 minutes after the onset of reperfusion (P > 0.05, ANCOVA).